What is Theralink Technologies, Inc. (THER)?

Theralink Technologies, Inc. (THER) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of THER?

The current price of THER is $0.00. Prices are updated in real time on Stocks360.

What is THER's price-to-earnings (PE) ratio?

THER's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

What is THER's market capitalization?

THER's market capitalization is $615,149.00, placing it in the small-cap tier.

Theralink Technologies, Inc. (THER)

Stock analysis · OTC · Healthcare · Biotechnology

$0.00

Market Cap

$615.15K

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

9.88

Day Range

$0.00 – $0.00

52-wk Range

$0.00 – $0.00

Avg Volume

N/A

Volume

110.00

Theralink Technologies, Inc. (THER) is a publicly traded company in the Healthcare sector. Latest price: $0.00. Market cap $615.15K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $0.00 2026-10-28 · $0.00 (+0.00%)

Earnings

Most Recent

Dec 31, 2023

EPS $0.16 vs est. $1.39

Missed by $1.23

Proprietary Signals

Signal snapshot temporarily unavailable.

About Theralink Technologies, Inc.

Theralink Technologies, Inc., headquartered in Golden, Colorado, is a commercial-stage enterprise specializing in precision medicine and the generation of crucial molecular data. The company is dedicated to advancing and bringing to market innovative cancer immunotherapy products. Utilizing its proprietary platform, which focuses on phosphoprotein and protein biomarkers, alongside its sophisticated laboratory-developed test (LDT) technology, Theralink addresses diverse aspects of oncology and pharmaceutical research. Through their specialized Theralink Reverse Phase Protein Array assays, they provide highly accurate oncology data. This information enables the biopharmaceutical industry and clinical oncologists to more precisely predict which patients will respond to, or be resistant to, both FDA-approved and investigational drug treatments. Ultimately, Theralink's diagnostic assays deliver vital, actionable insights that benefit physicians, patients, and biopharmaceutical companies operating within the field of cancer care. The company adopted its current name, Theralink Technologies, Inc., in September 2020, having previously operated as OncBioMune Pharmaceuticals, Inc.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	1.01×
P/B	-0.00×
PEG	0.00×
P/FCF (TTM)	-0.10×
EV / EBITDA	-2.22×
EV / Sales	31.94×
Earnings Yield	-502438.52%
Free Cash Flow Yield	-965.33%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$19.38M
Revenue (TTM)	$606.80K
Net Income (TTM)	-$3.09B
Free Cash Flow (TTM)	$20.11M
Net Debt	$18.76M
Working Capital	-$38.57M
Gross Margin	79.20%
Operating Margin	-1479.80%
Net Margin	-5093.56%
Return on Equity	147.47%
Return on Invested Capital	48.92%